When lymphoma is discovered to affect the B cells, prognosis is generally pretty good almost regardless of subtype. It will almost surely be better than the prognosis for T-cell lymphomas, in large part because B cell lymphomas account for as much as 85% of all Non-Hodgkin's lymphomas, so inevitably more research has gone into these diseases than into the T-cell lymphomas.
Perhaps the most important determination is whether the cancer is indolent (slow-growing) or aggressive. This determination is made by the pathologist who reviews slides from the patient's biopsy.
Watch & Wait
Radiotherapy
Chemotherapy
Although there are several chemotherapeutic drugs used against lymphomas, the most common are cyclophosphamide, doxorubicin, vincristine, prednisone and Rituxan When administered together, this is known as R-CHOP combination chemotherapy, the most commonly used chemotherapy treatment in B cell lymphomas.
Immunotherapy
Radioimmunotherapy (RIT)
This is an emerging treatment option for the indolent subgroup of lymphomas, especially follicular lymphoma.
Two RIT options are currently in use:
Although there are differences between these two therapies, both function the same way: They take a monoclonal antibody and attach to it a radioactive isotope, which is injected into the body. The monoclonal antibody seeks out certain lymphocytes and attaches on to them, then delivers the radioactive payload.
These therapies are administered like chemotherapy (through infusions) but kill cancer cells like radiation.
Hematopoietic Stem Cell Transplantation
Photo: Pexels